Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Archives of Dermatological Research|October 22, 2016
CD164 identifies CD4<sup>+</sup> T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214Bernice M Benoit, Neha Jariwala, Geraldine O'Connor, et al.
JCI Insight|January 11, 2019
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphomaPablo Vieyra-Garcia, Jack D Crouch, John T O'Malley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytesMonika Kasprzycka, Qian Zhang, Agnieszka Witkiewicz, et al.
Cancer Immunology Research|June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cellsShujing Liu, Alain H Rook, Alexander C Huang, et al.
Journal of the American Academy of Dermatology|December 15, 2010
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Elise A Olsen, Alain H Rook, John Zic, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Dermatology and Therapy|November 24, 2021
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and ManagementAmy C M Musiek, Kerri E Rieger, Martine Bagot, et al.
Cancer Cell|June 15, 2016
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in CancerMarco Napoli, Avinashnarayan Venkatanarayan, Payal Raulji, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Archives of Dermatological Research|October 22, 2016
CD164 identifies CD4<sup>+</sup> T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214Bernice M Benoit, Neha Jariwala, Geraldine O'Connor, et al.
JCI Insight|January 11, 2019
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphomaPablo Vieyra-Garcia, Jack D Crouch, John T O'Malley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytesMonika Kasprzycka, Qian Zhang, Agnieszka Witkiewicz, et al.
Cancer Immunology Research|June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cellsShujing Liu, Alain H Rook, Alexander C Huang, et al.
Journal of the American Academy of Dermatology|December 15, 2010
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Elise A Olsen, Alain H Rook, John Zic, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Dermatology and Therapy|November 24, 2021
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and ManagementAmy C M Musiek, Kerri E Rieger, Martine Bagot, et al.
Cancer Cell|June 15, 2016
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in CancerMarco Napoli, Avinashnarayan Venkatanarayan, Payal Raulji, et al.
Pageof 10